One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern oncologic pharmacology is to develop novel strategies to overcome CCA chemoresistance either by increasing drug specificity, such as in targeted therapies aimed to inhibit receptors with tyrosine kinase activity, or to increase the amounts of active agents inside CCA cells by enhancing drug uptake or reducing efflux through export pumps. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.

Chemoresistance and chemosensitization in cholangiocarcinoma / Marin, Jose J. G.; Lozano, Elisa; Herraez, Elisa; Asensio, Maitane; Di Giacomo, Silvia; Romero, Marta R.; Briz, Oscar; Serrano, Maria A.; Efferth, Thomas; Macias, Rocio I. R.. - In: BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE. - ISSN 0925-4439. - 1864:4(2018), pp. 1444-1453. [10.1016/j.bbadis.2017.06.005]

Chemoresistance and chemosensitization in cholangiocarcinoma

Di Giacomo, Silvia;
2018

Abstract

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern oncologic pharmacology is to develop novel strategies to overcome CCA chemoresistance either by increasing drug specificity, such as in targeted therapies aimed to inhibit receptors with tyrosine kinase activity, or to increase the amounts of active agents inside CCA cells by enhancing drug uptake or reducing efflux through export pumps. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
2018
biliary cancer; chemotherapy; liver cancer; multidrug resistance; targeted therapies; antineoplastic agents; apoptosis; bile duct neoplasms; bile ducts; cell survival; cholangiocarcinoma; drug delivery systems; drug resistance, multiple; drug resistance; neoplasm; epithelial cells; gene expression regulation, neoplastic; genetic therapy; humans; protein kinase inhibitors; receptor protein-tyrosine kinases; signal transduction; treatment outcome; molecular medicine; molecular biology
01 Pubblicazione su rivista::01a Articolo in rivista
Chemoresistance and chemosensitization in cholangiocarcinoma / Marin, Jose J. G.; Lozano, Elisa; Herraez, Elisa; Asensio, Maitane; Di Giacomo, Silvia; Romero, Marta R.; Briz, Oscar; Serrano, Maria A.; Efferth, Thomas; Macias, Rocio I. R.. - In: BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE. - ISSN 0925-4439. - 1864:4(2018), pp. 1444-1453. [10.1016/j.bbadis.2017.06.005]
File allegati a questo prodotto
File Dimensione Formato  
Marin_Chemoresistance_2018.pdf

solo gestori archivio

Note: https://www.sciencedirect.com/science/article/pii/S0925443917302004?via=ihub
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 594.62 kB
Formato Adobe PDF
594.62 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1276806
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 84
social impact